Description
Comprehensive Guide to Abec-L Tablet (Abacavir and Lamivudine)
Abec-L Tablet is a fixed-dose combination prescription antiretroviral medicine manufactured by Emcure Pharmaceuticals Ltd. Each film-coated tablet contains two active pharmaceutical ingredients:
-
Abacavir Sulfate: Equivalent to 600 mg of Abacavir
-
Lamivudine: 300 mg
Abec-L is prescribed under specialist medical supervision to treat Human Immunodeficiency Virus type 1 (HIV-1) infection in adult and adolescent patients.
It serves as a dual nucleoside reverse transcriptase inhibitor (NRTI) backbone therapy.
It must always be combined with at least one other antiretroviral medicine from a different drug class (such as an integrase strand transfer inhibitor or a protease inhibitor) to lower viral load, support immune health, and prevent opportunistic infections.
Quick Product Fact Sheet
| Feature | Details |
| Brand Name | Abec-L Tablet (A Bec L) |
| Active Ingredients | Abacavir (600 mg) + Lamivudine (300 mg) |
| Manufacturer | Emcure Pharmaceuticals Ltd. |
| Therapeutic Class | Antiretroviral (Anti-HIV) |
| Pharmacological Class | Nucleoside Reverse Transcriptase Inhibitors (NRTIs) |
| Dosage Form | Film-coated oral tablet |
| Standard Dosage | One tablet once daily |
| Mandatory Pre-Test | HLA-B*5701 genetic blood screening |
How Abec-L Works
HIV is a retrovirus that infects and weakens the immune system, particularly CD4+ T-lymphocytes. Inside human cells, the virus relies on an enzyme called reverse transcriptase to copy its viral RNA into DNA, allowing it to integrate into human genetic material and replicate.
Both abacavir and lamivudine act as faulty building blocks to interrupt this process:
-
Once absorbed, abacavir converts into carbovir triphosphate, and lamivudine converts into lamivudine triphosphate.
-
These active substances mimic natural nucleotide bases and compete for incorporation into the growing viral DNA chain.
-
Because both compounds lack the essential chemical link (a 3′-OH group) required to attach additional nucleotides, DNA chain elongation terminates immediately.
-
This halts viral replication, reduces the amount of HIV in the bloodstream, and allows the immune system to recover.
Approved Clinical Uses
Abec-L Tablet is indicated for:
-
Treatment of HIV-1 Infection: Used as part of combination antiretroviral therapy (cART) for adults and pediatric patients weighing at least 25 kg (55 lbs).
-
It must always be taken alongside at least one additional anti-HIV medication to ensure complete viral suppression and prevent drug resistance.
Important Note: Abec-L does not cure HIV-1 infection, nor does it eliminate the risk of transmission to others if viral suppression is not maintained. Daily treatment is required to keep viral levels undetectable.
Mandatory Safety Screening: HLA-B*5701 Test
Before taking the first dose of Abec-L, a physician must test the patient for the HLA-B*5701 genetic allele.
-
Purpose: Patients carrying this specific genetic variant have a significantly higher risk of experiencing a severe, life-threatening Abacavir Hypersensitivity Reaction (HSR).
-
If the test is positive: You must never take Abec-L or any other medicine containing abacavir. Your healthcare provider will prescribe a different treatment backbone.
-
If the test is negative: You can safely initiate treatment, though you should remain aware of potential allergy symptoms.
Standard Dosage and How to Take
Abec-L must be taken strictly as prescribed by your infectious disease specialist:
-
Standard Adult & Adolescent Dose: One tablet taken orally once daily.
-
Weight Requirement: Approved for individuals weighing 25 kg or more.
-
Food Instructions: Can be taken with or without food. Taking it with a light meal can help minimize mild stomach discomfort.
-
How to Ingest: Swallow the tablet whole with a glass of water. Do not chew, crush, or break the tablet.
-
Daily Consistency: Take the tablet at the exact same time every day to maintain steady medicine levels in the bloodstream.
-
Missed Dose Protocol: If you miss a dose by less than 12 hours, take it right away. If you are within 12 hours of your next scheduled dose, skip the missed tablet and resume your regular timing. Never take two tablets at once.
Potential Side Effects & Clinical Management
Common Side Effects
-
Headache
-
Mild nausea or stomach cramps
-
Diarrhea
-
Fatigue or low physical energy
-
Dizziness
-
Difficulty sleeping (insomnia)
-
Mild skin rash
Serious Allergic Reaction (Hypersensitivity Warning)
Contact your doctor or visit an emergency room immediately if you develop symptoms from two or more of the following groups:
| Symptom Group | Warning Signs |
| Group 1 | Fever |
| Group 2 | Skin rash, redness, or hives |
| Group 3 | Nausea, vomiting, diarrhea, or severe abdominal pain |
| Group 4 | Extreme tiredness, body aches, or general malaise |
| Group 5 | Shortness of breath, dry cough, or sore throat |
Critical Warning: If Abec-L is discontinued because of a suspected hypersensitivity reaction, never take Abec-L or any abacavir-containing medicine again. Re-challenging can trigger an immediate, fatal drop in blood pressure and organ failure.
Other Serious Adverse Reactions
-
Lactic Acidosis: A dangerous buildup of lactic acid in the blood, marked by deep muscle pain, rapid breathing, severe stomach pain, and profound fatigue.
-
Severe Hepatomegaly with Steatosis: Enlarged, fatty liver causing yellowing of the skin or eyes (jaundice), dark urine, and light stools.
-
Hepatitis B Exacerbation: For patients co-infected with HIV and Hepatitis B, abruptly stopping Abec-L can trigger severe, acute liver failure due to the sudden withdrawal of lamivudine.
Precautions & Medical Monitoring
| Test / Evaluation | Recommended Frequency | Purpose |
| HLA-B*5701 Genetic Test | Mandatory before starting | Screens for high hypersensitivity risk. |
| HIV-1 Viral Load & CD4 Count | Baseline, at 4–8 weeks, then every 3–6 months | Monitors how effectively the regimen is suppressing the virus. |
| Hepatitis B & C Screening | Baseline before initiation | Screens for co-infections to prevent post-discontinuation flares. |
| Liver Function Tests (LFTs) | Baseline and periodic | Evaluates liver health and catches transaminase elevations early. |
| Kidney Function (eGFR / CrCl) | Baseline and periodic | Abec-L is not recommended for patients with CrCl below 30–50 mL/min. |
Drug Interactions & Substance Warnings
-
Alcohol: Ethanol slows down the breakdown of abacavir, raising its blood levels by roughly 40%. Limit or avoid alcohol to reduce liver strain and avoid worsened dizziness.
-
Methadone: Abacavir can increase the clearance of methadone, which may require a dosage adjustment of methadone.
-
Overlapping Antivirals: Do not take Abec-L alongside other medicines containing lamivudine (e.g., Epivir, 3TC) or emtricitabine (e.g., Truvada, Descovy).
-
Sorbitol-Containing Liquids: Frequent use of liquid medicines containing sorbitol can significantly reduce lamivudine absorption.
-
Cardiovascular Health: Inform your doctor if you have high blood pressure, diabetes, high cholesterol, or a history of smoking, as abacavir requires careful cardiovascular evaluation.
Special Population Guidance
| Population | Clinical Advice |
| Pregnancy | Can be used when prescribed by an HIV specialist. Extensive pregnancy registries indicate no increased risk of major birth defects. |
| Breastfeeding | Not recommended where safe formula is available, to eliminate the risk of postnatal viral transmission to the child. |
| Kidney Impairment | Not recommended when creatinine clearance is below 30–50 mL/min because this fixed-dose tablet cannot be adjusted. |
| Liver Impairment | Contraindicated in patients with moderate to severe liver disease (Child-Pugh Class B or C). |
| Pediatric Use | Suitable only for children weighing at least 25 kg who can swallow intact tablets. |
Storage and Handling Protocols
-
Store tablets at room temperature between 20°C and 25°C (68°F to 77°F).
-
Keep in the original container, tightly closed, in a dry place away from heat and direct sunlight.
-
Keep strictly out of reach of children and pets.
Frequently Asked Questions
Q1: Can Abec-L be taken as a single medicine to treat HIV?
No. Abec-L contains two NRTIs (abacavir and lamivudine) and must always be combined with at least one other anti-HIV drug from a different class to prevent the virus from mutating and developing resistance.
Q2: What should I do if I experience a fever and body aches after starting Abec-L?
Contact your healthcare provider immediately. A fever accompanied by stomach upset, fatigue, rash, or respiratory issues can be an early sign of an abacavir hypersensitivity reaction that requires immediate medical evaluation.
Q3: Can I drink alcohol while taking Abec-L?
It is advisable to limit or avoid alcohol. Drinking alcohol slows how fast your body clears abacavir, raising drug levels in your blood and putting extra stress on your liver.
Q4: Does Abec-L cure HIV?
No. Abec-L does not cure HIV. However, daily adherence keeps the virus suppressed to undetectable levels, protecting your immune system and preventing HIV progression.
Medical Disclaimer
This clinical guide is strictly for informational and educational purposes and should not replace professional medical advice, diagnosis, or treatment.
Always consult a qualified infectious disease specialist or healthcare professional before initiating, modifying, or halting any antiretroviral therapy.
References
-
U.S. Food and Drug Administration (FDA):Epzicom (abacavir and lamivudine) Full Prescribing Information.
-
National Center for Biotechnology Information (NCBI):StatPearls: Abacavir/Lamivudine Clinical Pharmacology & Safety Profile.
-
MedlinePlus (U.S. National Library of Medicine):Abacavir and Lamivudine Monograph.
-
Clinical Info HIV.gov (U.S. Department of Health and Human Services):Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.
Reviews
There are no reviews yet.